Rocklatan header logo
MENU CLOSE

About glaucoma

Looking to learn more about open-angle glaucoma and ocular hypertension—and how your elevated eye pressure affects these conditions? Discover the connection below.

What is open-angle glaucoma?

Open-angle glaucoma (OAG) is a condition that occurs when the fluid (known as “aqueous humor”) in your eye is unable to drain properly. This increases the pressure within the eye, which can damage your optic nerve.


What does that mean? 
Vision loss.

If left untreated, open-angle glaucoma gradually damages the optic nerve, which may lead to vision loss—and that vision loss is often permanent. That means the best way to prevent further vision loss from OAG is to help slow the progression of the disease by reducing pressure within the eye.

Did you know?

Glaucoma is the 2nd leading cause of blindness worldwide—and only 50% of people with glaucoma know they have it.

What is ocular hypertension?

With OHT, the fluid in the front of the eye doesn’t drain properly, leading to a buildup of pressure—similar to glaucoma.

Unlike glaucoma, however, OHT may not initially affect your vision or damage your optic nerve, meaning you may not realize you have it. If left untreated, OHT may increase your risk of developing glaucoma down the road.


Learn about an elevated eye pressure treatment that can help prevent further vision loss from OAG or OHT

You can’t reverse vision loss, but you can help prevent it before it happens.

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Rocklatan® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as Rocklatan® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.

Rocklatan® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.

Rocklatan® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

Rocklatan® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.

Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact lenses should be removed prior to using Rocklatan®. Contact lenses can be reinserted 15 minutes following administration of Rocklatan®.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with Rocklatan®.

Adverse reactions

The most common side effect for Rocklatan® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%). Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.

Be sure to contact your doctor if you have any questions.

Please click here for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used together with other eye drops to lower high eye pressure/IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Rocklatan® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as Rocklatan® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.

Rocklatan® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.

Rocklatan® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

Rocklatan® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.

Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact lenses should be removed prior to using Rocklatan®. Contact lenses can be reinserted 15 minutes following administration of Rocklatan®.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with Rocklatan®.

Adverse reactions

The most common side effect for Rocklatan® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%). Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.

Be sure to contact your doctor if you have any questions.

Please click here for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used together with other eye drops to lower high eye pressure/IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.